• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多发性骨髓瘤的发生发展及治疗的生物学研究。

Biological research on the occurrence and development of multiple myeloma and its treatment.

机构信息

Department of Orthopaedics, Beijing Chao-Yang Hospital, Beijing, China.

出版信息

Immun Inflamm Dis. 2023 May;11(5):e850. doi: 10.1002/iid3.850.

DOI:10.1002/iid3.850
PMID:37249283
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10165958/
Abstract

INTRODUCTION

To review the pathogenesis and treatment of multiple myeloma (MM). MM is a hematological malignancy with abnormal plasma cell proliferation in bone marrow. Due to the emergence of drug resistance, MM is still an incurable malignancy, which requires further exploration of pathogenesis and effective therapeutic targets.

METHODS

In this paper, the method of literature review is adopted to obtain the information about MM. Based on the literature, comprehensive and systematic review is made.

RESULTS

MM is a complex pathophysiological process with great heterogeneity, mainly reflected in genomic instability and bone marrow microenvironment. At present, the treatment of MM has made great progress, proteasome inhibitors and immunomodulatory drugs are widely used in clinic. Allogeneic stem cell transplantation may be the only promising cure for MM, and its high transplant-related mortality limits its clinical application.

CONCLUSIONS

The future of MM treatment lies in the development of more targeted therapies, novel immunotherapies, and a better understanding of the disease's molecular and genetic basis.

摘要

简介

本文旨在综述多发性骨髓瘤(MM)的发病机制和治疗方法。MM 是一种血液系统恶性肿瘤,其特征为骨髓中异常浆细胞的增殖。由于耐药性的出现,MM 仍然是一种不可治愈的恶性肿瘤,这需要进一步探索发病机制和有效的治疗靶点。

方法

本文采用文献回顾的方法获取 MM 的相关信息。基于文献进行综合系统的回顾。

结果

MM 是一个具有高度异质性的复杂病理生理过程,主要表现为基因组不稳定性和骨髓微环境。目前,MM 的治疗已经取得了很大的进展,蛋白酶体抑制剂和免疫调节剂在临床上得到了广泛应用。异基因造血干细胞移植可能是 MM 唯一有希望的治愈方法,但较高的移植相关死亡率限制了其临床应用。

结论

MM 治疗的未来在于开发更有针对性的治疗方法、新型免疫疗法以及更好地理解疾病的分子和遗传基础。

相似文献

1
Biological research on the occurrence and development of multiple myeloma and its treatment.多发性骨髓瘤的发生发展及治疗的生物学研究。
Immun Inflamm Dis. 2023 May;11(5):e850. doi: 10.1002/iid3.850.
2
Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.靶向骨髓微环境中的免疫龛:多发性骨髓瘤免疫治疗的兴起。
Curr Cancer Drug Targets. 2017;17(9):782-805. doi: 10.2174/1568009617666170214103834.
3
Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.免疫疗法在靶向多发性骨髓瘤骨髓微环境中的作用:一种不断发展的治疗策略。
Pharmacotherapy. 2017 Jan;37(1):129-143. doi: 10.1002/phar.1871. Epub 2017 Jan 6.
4
Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment.骨髓微环境中的多发性骨髓瘤治疗。
Curr Oncol. 2022 Nov 21;29(11):8975-9005. doi: 10.3390/curroncol29110705.
5
Immunotherapy of multiple myeloma.多发性骨髓瘤的免疫治疗。
J Clin Invest. 2020 Apr 1;130(4):1565-1575. doi: 10.1172/JCI129205.
6
Monoclonal antibody-based immunotherapy for multiple myeloma.基于单克隆抗体的多发性骨髓瘤免疫疗法。
Immunotherapy. 2012 Sep;4(9):919-38. doi: 10.2217/imt.12.82.
7
Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs.多发性骨髓瘤中的异基因干细胞移植:免疫疗法与新药
Expert Opin Biol Ther. 2015 Jun;15(6):857-72. doi: 10.1517/14712598.2015.1036735. Epub 2015 Apr 12.
8
Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.剖析多发性骨髓瘤与骨微环境的关系揭示了新的治疗机会。
J Mol Med (Berl). 2016 Jan;94(1):21-35. doi: 10.1007/s00109-015-1345-4. Epub 2015 Oct 1.
9
The role of high-dose chemotherapy in the treatment of multiple myeloma: a controversy.大剂量化疗在多发性骨髓瘤治疗中的作用:一场争议。
Ann Oncol. 2000;11 Suppl 1:55-8.
10
Multiple myeloma: signaling pathways and targeted therapy.多发性骨髓瘤:信号通路与靶向治疗。
Mol Biomed. 2024 Jul 4;5(1):25. doi: 10.1186/s43556-024-00188-w.

本文引用的文献

1
Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple Myeloma.生物标志物及针对多发性骨髓瘤中 STAT3 信号的新兴策略
Cells. 2022 Mar 10;11(6):941. doi: 10.3390/cells11060941.
2
Carfilzomib inhibits the proliferation and apoptosis of multiple myeloma cells by inhibiting STAT1/COX-2/iNOS signaling pathway.卡非佐米通过抑制STAT1/COX-2/iNOS信号通路抑制多发性骨髓瘤细胞的增殖和凋亡。
Transl Cancer Res. 2022 Jan;11(1):206-216. doi: 10.21037/tcr-21-2534.
3
[Gene Mutation and Overexpression of Newly Diagnosed Multiple Myeloma Patients].[新诊断多发性骨髓瘤患者的基因突变与过表达]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022 Feb;30(1):166-169. doi: 10.19746/j.cnki.issn.1009-2137.2022.01.027.
4
Nelfinavir Induces Cytotoxicity towards High-Grade Serous Ovarian Cancer Cells, Involving Induction of the Unfolded Protein Response, Modulation of Protein Synthesis, DNA Damage, Lysosomal Impairment, and Potentiation of Toxicity Caused by Proteasome Inhibition.奈非那韦对高级别浆液性卵巢癌细胞具有细胞毒性,涉及诱导未折叠蛋白反应、调节蛋白质合成、DNA损伤、溶酶体损伤以及增强蛋白酶体抑制所导致的毒性。
Cancers (Basel). 2021 Dec 26;14(1):99. doi: 10.3390/cancers14010099.
5
Granzyme B and perforin produced by SEC2 mutant-activated human CD4 T cells and CD8 T cells induce apoptosis of K562 leukemic cells by the mitochondrial apoptotic pathway.SEC2 突变体激活的人 CD4 T 细胞和 CD8 T 细胞产生的 granzyme B 和 perforin 通过线粒体凋亡途径诱导 K562 白血病细胞凋亡。
Int J Biol Macromol. 2021 Nov 1;190:284-290. doi: 10.1016/j.ijbiomac.2021.08.225. Epub 2021 Sep 4.
6
Isatuximab: A Review of Its Use in Multiple Myeloma.依沙妥昔单抗:在多发性骨髓瘤中的应用评价。
Target Oncol. 2021 Sep;16(5):675-686. doi: 10.1007/s11523-021-00827-0. Epub 2021 Aug 5.
7
Developing next generation immunomodulatory drugs and their combinations in multiple myeloma.开发用于多发性骨髓瘤的下一代免疫调节药物及其联合用药方案。
Oncotarget. 2021 Jul 20;12(15):1555-1563. doi: 10.18632/oncotarget.27973.
8
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.isatuximab、卡非佐米和地塞米松用于复发多发性骨髓瘤(IKEMA):一项多中心、开放标签、随机3期试验
Lancet. 2021 Jun 19;397(10292):2361-2371. doi: 10.1016/S0140-6736(21)00592-4. Epub 2021 Jun 4.
9
Fas-Fas Ligand Interplay in the Periphery of Salivary Gland Carcinomas as a New Checkpoint Predictor for Disease Severity and Immunotherapy Response.唾液腺癌外周中Fas-Fas配体相互作用作为疾病严重程度和免疫治疗反应的新检查点预测指标
Biomedicines. 2021 Apr 8;9(4):402. doi: 10.3390/biomedicines9040402.
10
Synergistic interaction between HDAC and MCL-1 inhibitors through downregulation of BCL-XL in multiple myeloma.HDAC与MCL-1抑制剂通过下调多发性骨髓瘤中的BCL-XL产生协同相互作用。
Haematologica. 2021 Sep 1;106(9):2516-2521. doi: 10.3324/haematol.2020.277152.